As we know, some molecular markers, such as MGMT (O6-methylguanine DNA methyltransferase) (Binabaj et al., 2018), isocitrate dehydrogenase (IDH) (Kwon et al., 2019), epidermal growth factor receptor (EGFR) (Chistiakov, Chekhonin & Chekhonin, 2017) and phosphatase and tensin homolog (PTEN) (Koshiyama et al., 2017) that have contributed to personalized therapeutic approaches and targeted anti-glioblastoma therapies have been routinely tested in glioblastoma patients clinically (Yin et al., 2019). This evidence concerns the gene MGMT and glioblastoma.